Research Study
Nifty Biosimilar
Aflibercept (Zaltrap®) is a recombinant fusion protein with complex post-translational modifications. Therefore deep understanding of biosimilar development is required to develop a biosimilar like Aflibercept.
UGA Biopharma has successfully completed a large number of biosimilar for several international biopharmaceutical companies. Our know-how and longstanding expertise in cell line development, bioprocess optimization, downstream development and analytics makes us the leading partner for your biosimilar development projects
